Important Program Updates

PRODUCT UPDATES

  • Effective June 9, 2026 the AZ&Me program is now accepting applications for BAXFENDY
  • Click HERE to sign in and apply online or click HERE to download and fax the application

  • Effective May 1, 2026, the AZ&Me program will no longer accept new patients for FARXIGA and XIGDUO XR
  • Actively enrolled patients will continue to receive assistance for FARXIGA and XIGDUO XR until December 31, 2026
  • Communications regarding this change will be sent to currently enrolled patients and their providers in April 2026

  • Why are FARXIGA and XIGDUO XR being removed from AZ&Me Prescription Savings Program?
  • Beginning in April, several generic equivalents for FARXIGA and XIGDUO XR will become available. As a result of this broad generic availability, FARXIGA and XIGDUO XR will be removed from the AZ&Me Prescription Savings Program by the end of 2026.
  • How long will patients continue to receive FARXIGA and XIGDUO XR support?
  • Patients currently enrolled in AZ&Me can continue to receive support until December 31, 2026.
  • What is the last day to request a refill?
  • For patients currently enrolled in AZ&Me, the final day to request a refill will be December 15, 2026.
  • Who should I contact for refill requests or program questions?
  • Patients and their Healthcare Providers can get additional program information and manage refill requests by visiting the AZ&Me website: www.azandme.com or they can speak to an AZ&Me representative by calling 1-800-AZandMe (1-800-292-6363), Monday through Friday, 9:00 AM–6:00 PM ET.
  • Are there any exceptions or extensions beyond December 31, 2026?
  • There are no exceptions or extensions. FARXIGA and XIGDUO XR will be fully removed from AZ&Me on December 31, 2026.
  • Where can patients receive assistance with FARXIGA and XIGDUO XR if AZ&Me will no longer provide it to them?
  • Depending on the patient’s situation, the following resources may be able to provide assistance:

PROGRAM UPDATES

  • Program income eligibility requirements will remain at 300% of the Federal Poverty Level (FPL) for Primary and Specialty products
  • Program income eligibility requirements will remain at 500% of FPL for Rare Disease products

  • As a program of last resort, the AZ&Me program will continue to require that new and re-enrolling Specialty and Rare Disease Medicare patients who meet program eligibility requirements and are Conditionally Approved pursue other assistance options including independent nonprofit organizations (INOs) grants before completing their enrollment for 2026
  • INO grants can help eligible patients with costs such as copays, premiums, deductibles, and out-of-pocket expenses for their medication(s)
  • If the patient does not qualify for applicable INO assistance or all available funds are closed, the patient must complete the Specialty & Rare Disease Medicare Enrollment Form as proof of denial or fund closure from three (3) INOs
    • The completed form may be uploaded on the AZ&Me website, faxed to 1-877-239-0867
or opted-in patients may utilize the AZ&Me Digital Assistant to complete and submit the form
    • The form must be received on/after January 1, 2026
    • If submitting proof of fund denials, the patient must attach copies/screenshots from three (3) INOs with the completed form
    • Denial letters/screenshots must be time and date stamped on/after January 1, 2026
      • Must be received within 15 days of time/date stamp
    • If the patient obtains an INO grant that does not cover the full $2,100 Medicare Out-of-Pocket maximum, that INO will count as 1 of 3 required INO denials/fund closures
      • Patients should still pursue these grants as many can be utilized for insurance premiums and other medical expenses
    • If the patient does not have a Part D plan or does not have coverage for the product, they should indicate this on the Specialty & Rare Disease Medicare Enrollment Form
      • Medicare patients who do not have a Part D plan or coverage for the requested product through their Part D plan will not be required to submit proof of three INO fund denials or closures
    • For a list of some independent charitable assistance foundations that may be able to assist, patients can visit:
  • Once the completed Specialty & Rare Disease Medicare Enrollment Form and applicable supporting documentation are received and confirmed, the Conditionally Approved patient’s enrollment will be fully approved, and a Final Approval notification will be sent to the patient and their provider

  • If a patient is no longer in need of assistance from AZ&Me, the patient and their provider have three options to withdraw from the program:
    • Use the Sign In button above to access the patient's AZ&Me Dashboard and click the “Withdraw from Program” link under Other Program Tasks
    •  Complete the AZ&Me Withdrawal Form
      • The completed form may be:
    •  Call 1-800-AZandMe (1-800-292-6363), Monday through Friday 9:00 AM-6:00 PM ET, to speak with an AZ&Me Representative
    •  

  • To qualify for the AZ&Me program, patients must not have any commercial (private or employer sponsored) insurance or insurance through a government program other than Medicare
  • Commercially insured Specialty & Rare Disease patients who meet all other program eligibility and fall within one of the following coverage categories may request a Reconsideration:
    • Community Collective Cost-Sharing Plan Denialthe patient must provide Notice of Health Insurance Non-coverage letter from the plan dated in the current calendar year
    • Exhausted Product Copay Card BenefitAZ&Me will confirm that the patient’s copay card has been exhausted
    • Insurance Denialthe patient must provide proof of insurer denial or non-coverage dated in the current calendar year
    • No Prescription Drug Plan Benefitthe patient must provide documentation of plan details/no prescription drug plan dated in the current calendar year
  • To request an Insurance Coverage Reconsideration, the patient’s prescribing physician must complete and sign the AZ&Me Insurance Coverage Reconsideration Form

For any questions or further assistance, please contact us at:
1-800-AZandMe (1-800-292-6363), Monday through Friday, 9:00 AM6:00 PM ET

Frequently Asked Questions - FAQs About the Updates

No, AZ&Me income eligibility requirements will remain the same in 2026

  • Annual adjusted gross household income must be at or below 300% of the Federal Poverty Level (FPL) for Primary and Specialty products (no change)
  • Annual adjusted gross household income must be at or below 500% of the Federal Poverty Level (FPL) for Rare Disease products (no change)

AZ&Me should always be positioned as a program of last resort. As such, Specialty and Rare Disease Medicare patients should exhaust other avenues of assistance, including independent charitable assistance foundations, prior to completing their 2026 enrollment.

While not required, the AZ&Me Digital Assistant allows patients to quickly and easily access real-time enrollment information, submit updated consent (required for all Conditionally Approved patients) and submit proof of denial or fund closure from 3 independent charitable assistance foundations (required for Conditionally Approved Specialty and Rare Disease Medicare patients).